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Abstract
Purpose:  To  evaluate  the  possible  use  of  soft  contact  lenses  (CL)  to  improve  the  secretagogue
role of  diadenosine  tetraphosphate  (Ap4A)  promoting  tear  secretion.
Methods:  Two  conventional  hydrogel  CL  (Omaﬁlcon  A  and  Ocuﬁlcon  D)  and  two  silicone  hydrogel
(SiH) CL  (Comﬁlcon  A  and  Balaﬁlcon  A)  were  used.  Ap4A  was  loaded  into  the  lenses  by  soaking
in  a  1  mM  Ap4A  solution  during  12  h.  In  vitro  experiments  were  performed  by  placing  the  lenses
in  multi-wells  during  2  h  containing  1  ml  of  ultrapure  water.  100  l  aliquots  were  taken  at  time
zero  and  every  minute  for  the  ﬁrst  10  min,  and  then  every  15  min.  In  vivo  experiments  were
performed  in  New  Zealand  rabbits  and  both  the  dinucleotide  release  from  SiH  and  tear  secretion
were  measured  by  means  of  Schirmer  strips  and  high-pressure  liquid  chromatography  (HPLC)
analysis.
Results:  Ap4A  in  vitro  release  experiments  in  hydrogel  CL  presented  a  release  time  50  (RT50)  of
3.9  ±  0.2  min  and  3.1  ±  0.1  min  for  the  non-ionic  and  the  ionic  CL,  respectively.  SiH  CL  released
also  Ap4A  with  RT50 values  of  5.1  ±  0.1  min  for  the  non-ionic  and  2.7  ±  0.1  min  for  the  ionic  CL.
In  vivo  experiments  with  SiH  CL  showed  RT50 values  of  9.3  ±  0.2  min  and  8.5  ±  0.2  min  for  the
non-ionic  and  the  ionic  respectively.  The  non-ionic  lens  Ap4A  release  was  able  to  induce  tear
secretion  above  baseline  tear  levels  for  almost  360  min.
Conclusion:  The  delivery  of  Ap4A  is  slower  and  the  effect  lasts  longer  with  non-ionic  lenses  than
ionic lenses.
© 2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Administración  in  vitro  e  in  vivo  del  secretagogo  diadenosín  tetrafosfato  utilizando
lentes  de  contacto  blandas  convencionales  y  de  hidrogel  de  silicona
Resumen
Objetivo:  Evaluar  el  posible  uso  de  las  lentes  de  contacto  blandas  (LC)  para  mejorar  la  función
secretagoga del  diadenosín  tetrafosfato  (Ap4A),  de  cara  a  promover  la  secreción  lagrimal.
Métodos: Se  utilizaron  dos  lentes  de  contacto  convencionales  de  hidrogel  (Omaﬁlcon  A  y  Ocu-
ﬁlcon D)  y  dos  lentes  de  contacto  de  hidrogel  de  silicona  (SiH)  (Comﬁlcon  A  y  Balaﬁlcon  A).  Se
cargó  Ap4A  en  las  lentes,  mediante  inmersión  en  una  solución  de  1  mM  de  Ap4A  durante  12  h.  Se
realizaron  experimentos  in  vitro,  colocando  las  lentes  durante  2  h  en  pocillos  con  1  ml  de  agua
ultra  pura.  Se  tomaron  100  l  de  muestra  en  el  momento  inicial,  y  a  cada  minuto  durante  los
primeros  diez  minutos,  y  posteriormente  cada  15  minutos.  Se  realizaron  experimentos  in  vivo
con  conejos  de  Nueva  Zelanda,  midiéndose  tanto  la  liberación  de  nucleótido  a  partir  de  las
lentes  SiH  como  la  secreción  de  lágrimas,  mediante  tiras  de  Schirmer  y  análisis  cromatografía
líquida  de  alta  presión  (HPLC).
Resultados: Los  experimentos  de  liberación  in  vitro  de  Ap4A  en  las  lentes  de  contacto  de  hidro-
gel presentaron  un  tiempo  de  liberación  50  (RT50),  de  3,9  ±  0,2  min  y  3,1  ±  0,1  min  para  las
lentes  no  iónicas  e  iónicas,  respectivamente.  Las  lentes  de  contacto  de  SiH  liberaron  tam-
bién  Ap4A  con  valores  RT50 de  5,1  ±  0,1  min  para  las  lentes  no  iónicas,  y  de  2,7  ±  0,1  min  para
las  lentes  iónicas.  Los  experimentos  in  vivo  con  las  lentes  de  SiH  mostraron  valores  RT50 de
9,3  ±  0,2  min  y  de  8,5  ±  0,2  min  para  las  lentes  no  iónicas  y  las  iónicas,  respectivamente.  La
liberación  de  Ap4A  de  las  lentes  no  iónicas  fue  capaz  de  inducir  la  secreción  de  lágrimas  por
encima  de  los  niveles  basales,  durante  casi  360  min.
Conclusión: La  liberación  de  Ap4A  es  más  lenta,  y  el  efecto  es  más  duradero  con  lentes  no
iónicas que  con  lentes  iónicas.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
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ntroduction
he  eye  is  characterized  by  its  complex  structure  and  high
esistance to  foreign  substances  including  drugs  that  makes
cular drug  delivery  a  major  challenge.  Currently,  more
han 90%  of  ophthalmic  drugs  are  delivered  in  the  form  of
olutions or  suspensions.1 These  conventional  ophthalmic
ormulations generally  show  low  ocular  bioavailability  due
o various  factors  such  as  reﬂex  tearing  and  blinking,  non-
roductive absorption,  nasolacrimal  drainage,  metabolic
egradation, and  the  relative  impermeability  of  the  corneal
pithelial membrane.  As  a  consequence  of  these  physiolog-
cal and  anatomical  constraints,  ophthalmic  drugs  have  a
hort residence  time  of  less  than  5  min  and  only  1--5%  of
pplied drug  is  effectively  absorbed.2 The  drug  loss  to  the
ystemic circulation  leads  to  drug  wastage  and  it  could  cause
ndesirable side  effects.
To  overcome  the  low  ocular  bioavailability  associated
ith topical  ocular  administration  of  drugs  by  eye  drops,
lternative drug  delivery  systems  have  been  proposed.3,4 In
his context,  soft  contact  lenses  (CL)  are  emerging  as  new
ehicle for  ophthalmic  drug  delivery.  In  the  eye,  CL  are  sepa-
ated off  the  cornea  by  a  thin  ﬂuid  layer  called  post-lens  tear
lm. The  ﬂuid  in  the  post-lens  tear  ﬁlm  is  not  well-mixed
ith the  remaining  tear  ﬂuid.  The  mixing  time  of  the  ﬂuid
n the  post  lens  tear  ﬁlm  with  the  outer  tear  ﬂuid  is  about
0 min.5 Thus,  ophthalmic  drugs  released  from  the  soft  CL
ould have  a  residence  time  in  front  of  the  cornea  for  at
east 30  min  compared  to  less  than  5  min  for  eye  drops.6 The
nhanced residence  time  leads  to  improved  drug  bioavail-
bility that  would  reduce  the  amount  of  drug  that  enters  in
s
w
i
dhe  systemic  circulation,  thus  potentially  improving  thera-
eutic efﬁcacy  and  preventing  side  effects.
The  potential  of  CL  loading  conventional  drugs  used  to
reat anterior  eye  disorders  have  been  already  explored.7--10
ost  of  the  studies  performed  have  been  in  vitro  assays,
hereas in  vivo  validation  of  therapeutic  contact  lenses  has
ot  been  so  widely  examined.
Commercially  available  CL  are  manufactured  using  dif-
erent materials  presenting  signiﬁcant  changes  in  their
ater content  and  electrostatic  charge  among  other  char-
cteristic properties.11 These  material  variations  can  have  a
elevant effect  on  the  CL--drug  interaction,  and  thus  affect
ates of  drug  uptake  and  release.
Initial  studies  were  developed  soaking  hydrophilic  con-
entional soft  contact  lens  based  on  poly  (2-hydroxyethyl
ethacrylate) (pHEMA)  hydrogels.11--15 However,  in  the  last
ears, highly  oxygen-permeable  soft  CL  based  on  siloxane
ontaining hydrogels,  have  also  been  tested.16--20 As  silicone-
ydrogel (SiH)  contact  lenses  transmit  more  oxygen  than
onventional materials,  thus,  diminishing  in  most  of  the
ases the  clinical  hypoxic  signs  associated  with  extended
ear of  hydrophilic  contact  lenses,  they  may  represent  a
etter option  to  develop  extended  drug  delivery  vehicles
or therapeutic  applications.
New substances  are  emerging  as  potential  agents  for  the
reatment of  dry  eye.  Among  these,  dinucleotides  are  inter-
sting candidates  as  their  topical  application  induces  tear
ecretion stimulating  the  secretion  of  tear  ﬂuid  (water)  as
ell as  the  secretion  of  mucins  (key  proteins  contribut-
ng to  maintenance  and  lubrication  of  the  tear  ﬁlm).  The
inucleotide diadenosine  tetraphosphate  (Ap4A)  markedly
Contact  lens  delivery  of  Ap4A  207
Table  1  Characteristics  of  the  contact  lenses  used  along  this  study.
Lenses  Hydrogel  conventional
non-ionic
Hydrogel
conventional  ionic
Silicone  hydrogel
non-ionic
Silicone
hydrogel ionic
Commercial  name  (supplier)  Proclear
(CooperVision)
Biolens  55  (Tiedra)  Bioﬁnity
(CooperVision)
Pure Vision  II
(Bausch &
Lomb)
Material  name  (USAN)  Omaﬁlcon  A  Ocuﬁlcon  D  Comﬁlcon  A  Balaﬁlcon  A
Water  content  (%)  62  55  48  36
Center  thickness  in  mm  (at  −3.00  D)  0.065  0.070  0.080  0.070
Oxygen  permeability  (×10−11)  Dk  27  --  128  91
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increased  tear  production  to  around  a  60%  above  normal
tear values  in  New  Zealand  White  rabbits.21 Likewise,  the
application of  other  dinucleotide,  diuridine  tetraphosphate
(Up4U, INS365,  diquafosol),  induced  a  1.5-fold  transient
increase in  tear  ﬂuid  secretion  in  a  rat  dry  eye  model.22
Interestingly,  this  dinucleotide  has  been  under  development
as a  new  treatment  for  dry  eye23 and,  after  completion  of
clinical trials,  it  has  been  recently  launched  in  Japan  by
Santen Pharmaceutical.
The purpose  of  this  study  was  to  investigate  the  delivery
of the  dinucleotide  Ap4A  from  commercial  soft  CL  perform-
ing in  vitro  and  in  vivo  assays.  Furthermore,  to  obtain  an
indication of  the  clinical  feasibility  of  this  drug  delivery  sys-
tem to  treat  dry  eye  pathology,  we  measured  tear  secretion
induced by  Ap4A  soaked-soft  contact  lenses.
Methods
Materials
Four  commercially  available  CL,  including  two  conventional
hydrogel lenses  (Omaﬁlcon  A  and  Ocuﬁlcon  D)  and  two  SiH  CL
(Comﬁlcon  A  and  Balaﬁlcon  A),  which  properties  are  outlined
in Table  1,  were  evaluated  in  this  study.  All  lenses  had  a
power of  −3.00  D  and  base  curve  of  8.60  mm.  Diadenosine
tetraphosphate  (Ap4A)  was  purchased  from  Sigma--Aldrich
Chemicals (St.  Louis,  USA).  The  Schirmer  strips  (Tear  Flo  test
strips, HUB  Pharmaceuticals  Rancho  Cucamonga,  USA)  were
provided  by  Laboratorios  Lenticon  SA  (Spain).  All  chemicals
were of  reagent  grade  purchased  from  Merck  (Germany).
Animals
Four  male  New  Zealand  white  rabbits  (2.5  ±  0.5  kg)  were
used in  the  in  vivo  experimentation.  The  animals  were  kept
in individual  cages  with  free  access  to  food  and  water.
Rabbits were  submitted  to  12  h/12  h  light/dark  cycles.  All
the protocols  here  described  were  approved  by  the  Comité
de Experimentación  Animal  of  Complutense  University  which
follows the  tenets  of  the  European  Communities  Council
Directive (86/609/EEC).Ap4A  loading  into  contact  lenses
Commercial  CL  were  removed  from  their  original  blister
packs and  were  transferred  to  24-well  plate.  Ap4A  was
c
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l19.2  160  130
oaded  into  the  lenses  by  soaking  in  a  1  mM  Ap4A  solution
diluted in  saline  solution  sterile  at  0.9%  whose  properties
ere the  same  than  CL’  packaging  solutions).  The  lenses
ere soaked  overnight  for  12  h  simulating  a normal  cleaning
egime performed  by  wearers  of  contact  lenses.  The  con-
rol CL  was  soaked  in  saline  solution  at  0.9%.  At  the  end
f Ap4A  loading,  the  lenses  were  taken  out  and  the  excess
p4A  from  the  surface  was  removed  before  to  beginning  the
p4A  release  experiments.  The  procedure  was  the  same  for
‘in vivo’’  and  ‘‘in  vitro’’  studies.
p4A  release  ‘‘in  vitro’’  assays
or  each  release  experiment,  three  CL  of  each  lens  type
ere studied.  After  Ap4A  loading,  the  lenses  were  placed  in
ew well  containing  1  ml  ultrapure  water.  Samples  (aliquots
f 100  l)  were  removed  from  the  well  at  time  zero  and
very minute  for  the  ﬁrst  10  min,  and  then  at  t  =  15,  20,
0, 60,  90  and  120  min,  to  assess  the  quantity  of  Ap4A
eleased into  the  solution.  The  same  volume,  which  was
emoved in  each  sample,  was  replaced  with  ultrapure  water.
he Ap4A  release  dynamics  was  determined  by  measuring
he quantity  of  Ap4A  in  each  sample,  which  was  mea-
ured by  means  of  high-pressure  liquid  chromatography
HPLC).
p4A  release  ‘‘in  vivo’’  assays
he  in  vivo  experiments  were  done  with  SiH  contact  lenses,
hich were  loaded  with  Ap4A  as  described  above.  In  vivo
ssays study  two  topics,  the  dynamic  of  Ap4A  release
‘in vivo’’  via  CL  and  its  effect  on  tear  secretion.  Both
ere measured  by  means  of  Schirmer  strips.  Firstly,  base-
ine values  were  measured.  Then,  each  animal  received  to
ight eye  one  drop  of  10  l of  Ap4A  at  1  mM,  a  Comﬁlcon
 (non-ionic)  contact  lens  loaded  with  Ap4A  or  a  Balaﬁl-
on A  (ionic)  contact  lens  loaded  with  Ap4A.  In  each  case,
he contralateral  eye  receives  the  same  lens  but  without
p4A.  After  that,  tear  secretion  was  measured  using  the
chirmer test  without  anesthesia  at  t =  0,  5,  10,  15,  30,  45,
0, 90,  120  and  then  every  hour  during  6  h.  Tear  collection
as always  performed  following  a  van  Bijsterveld  modiﬁed
riterion.24 Brieﬂy,  the  Schirmer  strip  was  placed  on  the
emporal tarsal  conjunctiva  of  the  lower  lid  for  2  min25 with
he eyes  closed.  The  volume  of  tears  was  recorded  as  mil-
imeters of  moistened  strip,  and  the  wetted  ends  of  the
2 C.O.  Dominguez-Godinez  et  al.
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Figure  1  In  vitro  release  of  diadenosine  tetraphosphate  from
soft contact  lenses.  (A)  Representative  chromatographic  pro-
ﬁle showing  the  release  of  Ap4A  from  a  non-ionic  hydrogel
contact lens.  (B)  Comparative  in  vitro  release  of  Ap4A  from  non-
ionic and  ionic  hydrogel  lenses  following  the  protocol  described
in methods  (n  =  3).  (C)  Comparative  in  vitro  release  of  Ap4A
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chirmer  strip  were  placed  in  Eppendorf  tubes  containing
00 l  of  ultrapure  water,  until  the  HPLC  analysis  was  per-
ormed.
The reason  for  not  using  conventional  hydrogel  lenses
as the  problems  we  observed  when  these  lenses  were  ﬁt-
ed to  rabbit  eyes.  Due  to  the  low  frequency  of  blinking,
he rate  of  dryness  did  not  permit  us  to  perform  accurate
easurements and  therefore  we  decided  to  focus  on  SiH
enses.
ample  preparation  for  analysis
ample  from  ‘‘in  vivo’’  and  ‘‘in  vitro’’  assays  were  col-
ected after  the  corresponding  procedure  (see  above).
amples were  stored  in  Eppendorf  tubes  at  −20 ◦C  before
rocessing. The  treatment  was  based  on  the  protocol
escribed by  Lazarowski  and  co-workers.26 Brieﬂy,  samples
ere heated  at  98 ◦C  bath  for  2  min.  Then,  the  samples
ere incubated  in  ice  for  10  min  and  ﬁnally  the  residues
ere removed  by  centrifugation  at  13,000  rpm  for  10  min.
inally, the  supernatants  were  collected  for  HPLC  analy-
is.
PLC  procedures
he  chromatographic  system  consisted  of  a  Waters  1515  Iso-
ratic HPLC  pump,  a  2487  dual  absorbance  detector,  and  a
eodyne injector,  all  managed  by  the  software  Breeze  from
aters (Milford,  MA).  The  column  was  a  KromaPhase  100
18 (250  mm  in  length,  4.6  mm  in  diameter)  from  Scharlab.
he system  was  equilibrated  overnight  with  10  mM  KH2PO4,
 mM  tetrabutylammonium  (TBA),  21%  acetonitrile,  pH  7.5,
nd detection  of  nucleotides  was  performed  under  isocratic
onditions with  the  mobile  phase  described  above  at  a  ﬂow
ate of  2  ml/min.
After injection  of  100  l of  sample,  detection  was  mon-
tored at  254  nm.  Ap4A  peak  was  identiﬁed  comparing  their
etention time  with  the  one  of  a  commercial  standard.  The
uantiﬁcation was  performed  by  comparing  the  areas  under
he curves  with  those  of  known  amounts  of  commercial
tandard Ap4A.
tatistical  analysis
ll  data  are  presented  as  the  mean  ±  SD.  Due  to  the
imited sample  size,  comparisons  between  lenses  were
one using  non-parametric  statistical  analysis.  Differences
etween time  points  were  determined  by  Kruskal--Wallis
est. Repeated  measures  analysis  was  conducted  using
ilcoxon signed  ranks  test.  All  graphics  were  carried  out
y GraphPad  Prism  5  software  (GraphPad,  La  Jolla,  CA).
p4A  release  (decay  constant)  was  calculated  by  ﬁtting
he corresponding  curves  to  one  phase  exponential  decay
urve. From  this  analysis  it  was  possible  to  calculate  the
elease Time  50  (RT50),  which  corresponds  to  the  time
n which  the  lens  has  released  50%  of  the  maximum
p4A  measured.  With  this  analysis  it  has  been  also  pos-
ible to  obtain  the  rate  of  release  for  each  lens.  A  p
alue lower  than  0.05  was  considered  statistically  signiﬁ-
ant.
t
a
lrom non-ionic  and  ionic  silicon  lenses  following  the  protocol
escribed in  methods  (n  =  3).
esults
p4A  release  ‘‘in  vitro’’
he  release  of  the  dinucleotide  Ap4A  was  followed  by  HPLC
y measuring  its  absorbance  at  254  nm  wavelength.  As  pre-
ented in  Fig.  1A  for  a  non-ionic  hydrogel  lens,  where  a  series
f HPLC  injections  are  plotted,  the  release  of  the  loaded
inucleotide presented  a  maximal  release  at  2  min  after  the
n vitro  experiment  started.  After  this  maximal  peak,  the
mount of  released  Ap4A  was  gradually  diminishing  until  the
nd of  the  experiments  (360  min).
Four types  of  lenses  were  used  in  this  study,  two  conven-
ional hydrogel  lenses,  Omaﬁlcon  A  (ionic;  55%  hydration)
nd Balaﬁlcon  A  (non-ionic;  62%  hydration)  and  two  SiH
enses, Conﬁlcon  A  (ionic;  36%  hydration)  and  Balaﬁlcon  A
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Figure  2  In  vivo  release  of  diadenosine  tetraphosphate  from
silicon contact  lenses  and  effect  on  tear  secretion.  (A)  In  vivo
release of  Ap4A  from  non-ionic  and  ionic  silicon  contact  lenses
together with  a  topical  application  of  1  mM  Ap4A  (10  l)  (n  =  3).
(B) Variation  of  tear  secretion,  induced  by  Ap4A  released  from
non-ionic and  ionic  silicon  contact  lenses  together  with  a  topi-
cal application  of  1  mM  Ap4A  (10  l)  (n  =  3).  Zero  represents  the
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(non-ionic;  48%  hydration).  For  a  better  understanding,  the
study of  how  Ap4A  was  released  in  vitro  from  the  lenses
was grouped  by  lens  materials.  As  it  can  be  seen  in  Fig.  1B,
hydrogel lenses  presented  a  peak  of  1747  ±  175  pmol  and
1227 ±  120  pmol,  2  min  after  the  experiment  started,  for
the Omaﬁlcon  A  (non-ionic)  and  the  Oculﬁlcon  A  (ionic)
lens respectively  (p  =  0.017;  Wilcoxon  test).  Both  contact
lenses presented  release  time  50  (RT50)  of  3.9  ±  0.2  min
and 3.1  ±  0.1  min  for  the  Omaﬁlcon  A  and  Oculﬁlcon  A
lens respectively.  The  rate  of  the  released  of  Ap4A  per-
mitted us  to  obtain  decay  constant  (decay  rate)  values  of
0.17 ±  0.02  min−1 for  the  Omaﬁlcon  A  lens  and  a  value  of
0.22 ±  0.02  min−1 for  Ocuﬁlcon  A  lens  (all  the  experiments
n =  3).
When  the  same  protocol  was  performed  with  the  SiH
lenses, the  Comﬁlcon  A  (non-ionic)  lens  presented  a  peak  of
982 ±  130  pmol  of  Ap4A,  and  the  Balaﬁlcon  A  (ionic)  provided
a maximal  release  of  550  ±  78  pmol  of  Ap4A,  both  peaks
2 min  after  the  experiment  started.  (p  =  0.011;  Wilcoxon
test). The  RT50 for  both  lenses  were  5.1  ±  0.1  min  for  the
Comﬁlcon A  and  2.7  ±  0.1  min  for  the  Balaﬁcon  A  contact
lens. The  Ap4A  decay  constant  values  for  these  lenses  were
0.13 ±  0.01  min−1 for  the  Comﬁlcon  A  and  0.25  ±  0.04  min−1
for  the  Balaﬁlcon  A  lens  (n  =  3  in  all  experiments).
Ap4A  release  ‘‘in  vivo’’
Since  the  lens  that  provided  the  longest  RT50 value  was  the
Comﬁlcon A  (non-ionic)  lens,  we  took  this  material  for  our
‘‘in vivo’’  studies  in  New  Zealand  rabbits.  In  this  sense,  we
compared whether  or  not  the  ionic  nature  of  the  contact  lens
could be  a  relevant  aspect  considering  the  chemical  charac-
teristics of  the  dinucleotide  Ap4A.  In  Fig.  2A  is  presented  a
comparison between  the  Comﬁlcon  A  (non-ionic)  lens  with
the Balaﬁlcon  A  (ionic),  both  loaded  with  Ap4A,  and  also
the topical  application  of  the  dinucleotide,  in  New  Zealand
rabbits. The  maximal  Ap4A  concentration  released  was  pro-
vided by  the  Balaﬁlcon  A  lens,  with  a  peak  of  34.9  ±  7.0  M,
while the  Comﬁlcon  A  peak  was  14.2  ±  6.0  M  (p  =  0.034;
Wilcoxon test).  The  topical  application  of  Ap4A  presented
a peak  of  90.5  ±  9.0  M.
Interestingly,  the  way  the  two  lenses  and  the  topical
application of  Ap4A  was  released  ‘‘in  vivo’’,  demon-
strated that  the  lens  that  delivered  Ap4A  more  slowly
was the  Comﬁlcon  A  (non-ionic)  lens.  The  RT50 for  the
Comﬁlcon A,  Balaﬁlcon  A  and  topical  application  of  Ap4A
were, 9.3  ±  0.2  min,  8.5  ±  0.2  min  and  4.9  ±  0.1  min  respec-
tively (n  =  3).  Concerning  the  decay  constant,  the  values
obtained were  0.07  ±  0.05  min−1 for  the  Comﬁlcon  A  (non-
ionic) lens  and  0.08  ±  0.06  min−1 for  Balaﬁlcon  A  lens
(n =  3).
When  the  ability  of  the  lens-released  Ap4A  to  mod-
ify tear  secretion  was  tested  in  New  Zealand  rabbits,  it
was possible  to  see  that  the  longest  effect  on  tear  secre-
tion was  obtained  by  the  Ap4A  that  was  released  from  the
Comﬁlcon A  (non-ionic)  lens,  as  presented  in  Fig.  2B.  The
effect was  measurable  up  to  360  min,  compared  to  the
Balaﬁlcon A  (ionic)  which  lasted  less  than  1  h.  Interest-
ingly, the  topically  applied  Ap4A  although  producing  a  strong
effect, 12  mm  in  Schirmer  test,  its  effect  only  lasted  90  min
(n =  3).
c
c
F
taseline tear  secretion  which  corresponded  to  a  Schirmer  score
f 12  ±  1  mm.
iscussion
o  date,  there  are  no  published  data  regarding  the  deliv-
ry of  dinucleotides  from  CL  for  dry  eye  treatment  or  in
nother condition.  The  present  work  reports  the  ﬁrst  study
hat has  assessed  the  in  vitro  and  in  vivo  release  of  Ap4A
rom conventional  soft  CL.
We  have  chosen  two  conventional  hydrogel  lenses
Omaﬁlcon A  which  is  non-ionic  and  Ocuﬁlcon  D  which  is
onic) and  two  silicone-hydrogel  contact  lenses  (Comﬁlcon
 which  is  non-ionic  and  Balaﬁlcon  A  which  is  ionic)  with
imilar parameters  (diameter,  base  curve  and  center  thick-
ess), because  the  aim  of  the  assay  has  been  to  compare  the
ifferent behavior  in  the  Ap4A  loading  and  release  accord-
ng to  material  and  in  relation  to  surface  charge  properties
ionic or  non-ionic).  Incorporation  of  a drug  into  the  lens
an be  achieved  by  different  techniques  such  as  drug-loaded
olloidal nanoparticles,  molecular  imprinting,  or  soaking.8
or  this  ﬁrst  stage,  we  have  chosen  soaking  the  lenses  in
he dinucleotide  solution  because  is  the  simplest  way  to
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ncorporate  the  drug  into  conventional  soft  CL.  When  CL  are
oaked in  a  solution  containing  the  drug,  the  compound  dif-
uses into  the  gel-like  matrix  of  the  lens,  where  it  is  trapped
ong enough  to  be  released  when  transferred  to  the  tear
lm.27
A  number  of  research  groups  working  on  the  devel-
pment of  therapeutic  CL  have  focused  on  delivery  of
ry eye  medications  from  the  lenses.  Various  molecules
cting as  re-wetting  agents  such  as  hyaluronic  acid  or
ydroxypropyl methylcellulose  have  been  included  in  soft
L and  their  subsequent  release  has  been  analyzed.28--30
owever,  soaked  CL  with  hyaluronic  acid  solution  did  not
oad sufﬁcient  amounts  of  hyaluronic  acid  and  release  was
omplete in  less  than  1 h.29 Considering  the  inﬂammatory
tiology of  the  disease,  delivery  of  the  anti-inﬂammatory
rug cyclosporine  A  from  soaked  contact  lenses  has
lso been  proposed  for  dry  eye  treatment,  maintaining
yclosporine A  delivery  rates  within  the  therapeutic  win-
ow for  14  days.19 Our  in  vitro  outcomes  show  that  Ap4A
as released  at  least  2  h  with  all  soaked  contact  lenses,
eing the  SiH  non-ionic  lens  with  more  slowdown  release
ate.
Chemical properties  and  water  content  have  been  sug-
ested as  important  contact  lens  properties  inﬂuencing  drug
elivery.11 Conventional  hydrogel  CL  are  made  in  polyHEMA
hich are  hydrophilic,31 meanwhile  SiH  CL  have  various
iloxane-based monomers  and  therefore  the  material  is  less
ydrophilic.16 It  is  not  clear  if  the  release  is  correlated  with
he drug  hydrophilicity.11 In  our  study  it  would  be  expected
hat Ap4A  has  a  better  interaction  with  conventional  hydro-
el lenses  than  silicone-hydrogel  lenses,  because  of  its
ydrophilic properties.  In  fact,  hydrophilic  contact  lenses
elease more  dinucleotide  than  SiH  lenses  in  the  ﬁrst  min-
tes (see  Fig.  1).
Regarding  water  content,  drug  release  is  higher  in  CL
ith more  water  content.  Probably  this  is  due  to  water  sol-
ates and  carries  the  Ap4A  through  the  CL  material.32 Ap4A
elivery correlated  well  with  CL  water  content.  But  it  seems
hat hydrophilicity  and  water  content  are  not  the  main  fac-
ors inﬂuencing  the  dinucleotide  release.  The  ionic  charge
f the  contact  lens  materials  could  be  the  major  factor  in
p4A  delivery.  In  this  sense,  it  is  important  to  note  that
p4A  is  a  dinucleotide  presenting  four  phosphates  that  in
eutral pH  present  four  negative  charges.33 This  could  be
he reason  why  those  lenses  with  ionic  charge,  which  is  also
egative, may  repel  Ap4A.  This  may  produce  two  undesir-
ble effects,  either  a  poor  load  of  the  dinucleotide  or/and
 fast  release  form  the  lens  due  to  the  repulsion  between
he negative  charges  of  Ap4A  and  the  contact  lens  mate-
ial. Moreover,  the  fact  of  ionic  contact  lenses  to  provide  a
lightly longer  retention  of  the  dinucleotide,  strongly  sug-
ests that  among  some  factors  to  be  studied,  charge  and
ater content  of  the  lens  compete  for  both  the  loading  as
ell dinucleotide  release.  This  point  deserves  more  atten-
ion and  further  analysis.
Another important  difference  between  both  SiH  lenses
s the  presence  of  a  plasma  oxidation  surface  treatment  in
he ionic  lens  Balaﬁlcon  A,  which  is  not  present  in  the  non-
onic lens  Comﬁlcon  A.  Plasma  treatment  has  been  applied  to
he ﬁrst  generation  of  SiH  CL  in  order  to  counterbalance  the
ydrophobic nature  of  the  siloxane  moieties.  This  distinctive
haracteristic could  also  play  a  role  in  the  kinetics  of  Ap4A
C
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ptake  and  release  that  need  to  be  further  investigated  in
uture studies.
There are  several  in  vitro  studies  about  drug  delivery
rom CL  but  not  so  many  in  vivo  evaluating  the  in  vivo
elease performance.  New  Zealand  white  rabbit  and  bea-
le dog  are  the  most  commonly  used  models  in  drug
elivery from  CL.18,34--36 Initially,  we  wanted  to  evaluate
ll the  contact  lenses  studied  in  vitro  also  in  vivo,  but
he hydrogel  contact  lens  were  impossible  to  ﬁt  because
he lenses  were  dried  in  the  ﬁrst  hour  of  wear  and  the
ictitating membrane  expelled  the  lens  out  of  the  eye.
he Comﬁlcon  A,  a  non-ionic  SiH,  maintained  the  Ap4A
oncentration around  2  M  (value  established  as  a  concen-
ration necessary  to  increase  tear  secretion21)  during  60  min
n tear  ﬁlm,  compared  with  5  min  achieved  by  topical
dministration. The  effect  of  Ap4A  delivered  from  Com-
lcon A,  a  non-ionic  SiH,  on  the  tear  secretion  lasted
p 300  min,  5-fold  compared  with  Ap4A  presence  time  in
he ocular  surface.  It  appears  that  P2Y2 receptors  present
n the  main  lachrymal  and  accessory  glands37 are  stim-
lated by  Ap4A  and  this  effect  remains  when  the  levels
f the  dinucleotide  has  decreased  on  the  ocular  sur-
ace.
It is  known  the  involvement  of  Ap4A  in  the  ocular  surface
hysiopathology stimulating  tear  secretion  or  improving  the
ate of  corneal  wound  healing.  Therefore  the  dinucleotide
an act  on  the  lachrymal  gland  to  induce  tear  secretion
nd also  on  the  corneal  epithelium  accelerating  the  rate
f migration  during  wound  healing.38,39 Both  roles  can  be
nhanced when  Ap4A  is  delivered  from  CL.  In  particular,
nd talking  about  tear  secretion,  the  dinucleotide  it  could
rovide great  comfort  in  dry  eyes  and  it  could  be  partic-
larly helpful  for  preventing  CL  induced  dry  eye  and/or
cular injury.  Nevertheless,  it  is  necessary  to  be  careful
hen extrapolating  these  in  vivo  results  obtained  in  ani-
al models  to  humans  because  there  are  some  differences
etween species  that  could  affect  the  dinucleotide  release.
he most  important  difference  is  the  blinking  rate,  lower
n rabbits,40 due  to  its  role  in  the  natural  release  of  Ap4A41
nd  also  its  relevance  in  the  CL  wear.  In  this  sense,  it  would
e expected  better  results  with  humans,  since  they  blink
ore often  permitting  higher  tonic  levels  of  Ap4A  due  to
link shear  stress.41 Future  studies  should  be  conducted
n order  to  evaluate  the  release  rate  with  different  din-
cleotides concentrations.  Also,  it  could  be  interesting  to
est its  potential  delivery  slowdown  with  others  drug-loaded
echniques.
In summary,  we  have  demonstrated  that  it  is  possible
o use  commercially  available  CL  as  delivery  systems  for
 molecule  that  induces  tear  secretion.  Our  experiments
emonstrate that  the  delivery  of  Ap4A  is  slower  and  the
ffect last  longer  with  non-ionic  lenses  than  ionic  lenses
ut in  vitro  experiments  do  not  always  reﬂect  what  hap-
ens in  vivo,  suggesting  that  apart  from  in  vitro  approaches
n vivo  experiments  are  necessary  to  fully  evaluate  the
otential use  of  CL  as  devices  for  drug  delivery.onﬂict of interest
he  authors  do  not  have  any  ﬁnancial  interest  on  the  mate-
ials and  instruments  used  in  this  study.
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